The ShiftShapers Podcast
Change either paralyzes or energizes - the choice is yours. Hear from businesses and entrepreneurs who have become energized and who have profited by shaping the shifts in their markets and practices. Become a SHIFTSHAPERS INSIDER and get our latest download, advance notice of all podcasts, podcast summaries, and special INSIDER-ONLY content. INSIDER SIGN UP
The ShiftShapers Podcast
Ep #304: Innovation and Problem Solving - with Jayne Morgan, M.D.
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
This episode of The ShiftShapers Podcast is called "Innovation and Problem Solving, with Jayne Morgan, M.D." and today, host and Chief Transformation Strategist David Saltzman, together with Jayne, Director Of Innovation at Piedmont Healthcare, discuss innovation and how it is applied at Piedmont.
Also discussed is diversity in clinical trials; why it is lacking and the progress of making it more inclusive to more minorities. The role of the FDA is also clarified when it comes to making changes in addressing health gaps and producing solutions that affect all demographics of people.
What You’ll Learn From this Episode:
- 03:02Accelerator and devices at Piedmont
- 07:13 Digital-based innovation and ongoing projects
- 09:50 Process of innovation from concept to implementation
- 13:12 Diversity in clinical trials
- 17:38 Role of the FDA in clinical trial diversity
Quotes:
07:30 “We will be starting with hospital-based problems and systems, looking at process improvement… inventions that address specific pain, one’s within the hospital-system itself, inventions that perhaps can be a jump to some of the internal apps that we already currently use.”
10:03 “If you don’t have the fortitude, I would say that that is probably one of the largest factors that contributes to that large failure rate, is that people are not clear on what they’re getting into and what the time commitment is.”
13:54 “Access to clinical trials traditionally, and certainly in the United States, has not been something that has been readily available to minority communities. And there are a number of reasons for that. Number 1 reason is probably trust and trust in the system or lack thereof.”
16:59 “As we move forward into personalized medicine and customized medicine, genome mix, by whatever term that you know it, is we do not participate in trials and have a plethora of participation that represents a swathe across all of America, indeed across all of the world.”
18:03 “Now, unofficially, the FDA is continuing to move in that direction and more forward-thinking institutions are also beginning to move in that direction such that we can ensure that the health disparities, the health gap in these countries, don’t continue to widen, fueled and fed by lack of access to clinical trials.”
Piedmont Healthcare is pushing the boundaries on innovation and helping to solve some long-term problems. What are they doing? And what do your clients need to know? We'll find out on this episode of Shift Shapers.
AnnouncerChange either paralyzes or energizes. The choice is yours. You're listening to the Shift Shapers podcast. You're about to learn firsthand from businesses and entrepreneurs who have successfully shaped the shifts in their industries. Get ready to become the change you want to see. This episode is brought to you by Shift Shaper Strategies. In sales, if you confuse, you lose. Clarify your message so you win more clients, crush your sales goals, and build your practice. Learn more at ShiftShaper Strategies.com. And now, here's your host, Story Brand Certified Guide and Chief Transformation Strategist at Shift Shaper Strategies, David Saltzman.
DavidOn this episode of Shift Shapers, we're speaking with Dr. Jane Morgan. She has the title that I want. It's a very cool title. She is director of innovation. What could be better than that, especially if you're kind of geeky as I am, at Piedmont Healthcare. And they are the largest healthcare system in Georgia, and she is at their main campus, so she's a big googamoga. But we want to talk to her about two things today. One is about innovation, obviously, and what she sees from her rather unique vantage point. And then the other thing that we want to spend a little bit of time talking about is something that I wasn't aware of until Dr. Morgan brought it to my attention off-air. And it's a problem that is probably affecting your practice and some of your clients, and you may not even be aware of it. So with that, welcome, Dr. Morgan.
SPEAKER_01Thank you. I appreciate being here.
DavidOh, it's our pleasure. So how does one get to have a cool job title like Director of Innovation?
SPEAKER_01Well, you know, this entire innovation space is moving so rapidly, and as you can probably surmise with companies like Amazon, Apple, Google, titles morph, change, are very different from the way that they used to be. And so innovation has come up and is starting to come up increasingly within healthcare systems as we're looking for different ways to deliver health care and to deliver outstanding health care. And so I have the pleasure of being the first director of innovation for the Piedmont Healthcare Systems, a 25,000 employee healthcare system in the state of Georgia. And as you said, it's the largest health system in the state of Georgia. And I have the pleasure of being our first director of innovation and leading our accelerator.
DavidWell, that's that's really neat. So let's talk about the accelerator and what's going on there. What are some of the things that you're working on and what are the likely impacts that those might have on medical care in general and on the industry and other aspects of life?
SPEAKER_01Sure. So currently at Piedmont, we have five projects within our accelerator that we are moving forward, all at various stages of development. Generally, when you look at developmental stages, you start at phase zero, which is really starting from scratch. Where we really are sitting down working with the design team, moving on into phase one, phase two, where we have mature prototype development moving in towards manufacturing. And so we have all stages within our accelerator. We also have all classes. Class meaning class one being the type of device that will not require FDA approval and will be have a shorter route to get to market. Class two is somewhere in between, and class three are those devices that will have the highest regulatory hurdles that generally will be internal to the patient at some point or another. Our accelerator has devices in the cardiology, general surgery, primary, and gastroenterology space currently, and we will be hosting our pitch rounds in June looking for our next winner.
DavidSo are you are you largely focused on devices?
SPEAKER_01We are largely focused on devices, but rapidly moving into the digital space. And actually, quite a few applications this year for the pitch rounds at Piedmont have involved the digital space, and we have started to take a serious look at those. Originally, yes, we were focused really on devices, devices that will improve the health care of patients, include improve healthcare delivery, uh, focus on quality and safety, and continue to push Piedmont, you know, towards the leading edge of development and healthcare excellence. However, just as my title, Director of Innovation, and all the titles you see across the country begin to morph, we also are morphing and growing. We have to be flexible and adaptable, and have begun to take a look at quite a few digital patents and digital intellectual property that are coming through our system.
DavidSo when you decide on projects in the incubator, is it based on claims, frequency of a particular condition, or how do those decisions get made?
SPEAKER_01So there's a board, there we have a board that convenes, and that board serves as the judges for the pitch rounds, and those decisions are made based on a number of things. One, you know, does it fit in with the focus of quality and safety for our organization? Patient experience is also very important to us, and so it needs to fit within that. Earlier on, when we initially started our accelerator, it also needed to fit within a composition of what we were capable of doing as we were just starting and getting off the ground. We are now four or five years into it, continuing to mature, continuing to develop our infrastructure, and so we've been able to broaden the types of devices and the types of inventions that we can bring into our accelerator. We partner with the Global Center for Medical Innovation, which is housed on Georgia Tech's campus. They provide our engineering support as we build a team around the person who wins our pitch rounds. We have a legal team, regulatory support, engineering, clinical, and GCMI provides all of that engineering and that design expertise that we need in the development arena.
DavidSo to date, most of what you all have been looking at has been hospital-oriented?
SPEAKER_01Let me think about that. We have one that is a primary care invention that is not. It is not, it is definitely ambulatory oriented. The other, and that's true. So we have three. Three are definitely hospital-oriented. One is 100% ambulatory oriented, and one is a hybrid, can be both internal or external to the hospital. So, you know, I actually have not thought about it in that way before, but there you are.
DavidSo when you start thinking about broadening out into data-based and digital-based innovation, are you talking about things like predictive modeling or are you going further than that? Or is it still around hospital-based problems and systems?
SPEAKER_01Probably we will be starting with hospital-based problems and systems, looking at process improvement, process improvement inventions that address specific pain points within the hospital system itself, inventions that perhaps can be adjuncts to some of the internal apps that we already currently use, or any type of invention that improves the patient experience once they are within the hospital system. So those are the types of things this year that we'll probably give serious consideration to.
DavidCan you give our audience an example of something perhaps that you've worked on in the past that you've brought to fruition?
SPEAKER_01So we at currently we don't have, we're young, we don't have anything that has gone to fruition. I'll tell you where we are though. We have our second invention is at a series A fundraising round, so they're at that stage, and we have a serious company looking to make further investment to continue the development of that device. Our year three project is looking now towards manufacturing. We have a completely functioning prototype and looking now for uh manufacturing systems for injection molding and larger production, and then building out that executive team. So those two in general are the ones that probably have moved the furthest along. You know, as you and your audience may or may not know, you know, when you work in the innovation space or the startup space, which is you know another way people tend to look at it, startup companies, the success rate is probably less than 15%. Less than 15% of all startup companies really move on to success. And so this is quite an investment in our employees, an investment in our physicians, our investment in our physician assistants and nurse practitioners, in ensuring that they have a place to place their ideas, that they feel comfortable uh being creative and speaking up and feel empowered to provide suggestions that uh improve the system, and those suggestions can come from any corner of the hospital, from any any person in the hospital.
DavidIs it always such a long gestation period from concept to implementation in the innovation space, or is sometimes are there shorter durations as well?
SPEAKER_01Almost always. It's not short. So if you know, if you don't have the fortitude, I would say that that is probably this one of the largest factors that contributes to that large failure rate is that people are not clear on what they're getting into and what the time commitment is. You know, I came out of the industry of uh pharmaceuticals and device industry, and you know, in general, I led the cardiore renal drug development team at at Solvey Pharmaceuticals, and you know, from a drug from STEM to stern is almost a 10-year development period. You know, devices sometimes can be shorter depending on the need, and drugs can also have a shorter development time, especially if they're in the oncology space where there is a recognition of a higher degree of um acuity and need, and sometimes the bar can be a bit lower such that those drugs can get out. But in general, it's not a short process. Certainly if you have a class two or class three device, meaning the FDA will be involved at to some degree, either at a minor level or heavily, the you know, those devices will be regulated. And, you know, that regulatory process also adds both time and money. So I would not get into the startup space for you know quick results.
AnnouncerAnd now a word from our sponsor: it's a fact. Salespeople and organizations lose opportunities because they don't clearly communicate their value. In today's market, your story is your message. It should be crystal clear, perfectly arranged, and precisely targeted to attract the clients you want. As a certified story brand guide, we use the exclusive SB7 process to create that story and the websites and collateral that deliver it. If your message isn't cutting through the noise, we can help. Visit us at ShiftShaper Strategies.com to learn how we can help you find, clarify, and deliver a message that wins clients, crushes sales goals, and builds your practice. In sales, if you confuse, you lose. So learn more and schedule that call today at ShiftShaperstrategies.com. That's ShiftShaperStrategies.com. And now back to our discussion.
DavidDo other countries have similar regulatory structures? And if they don't, does that affect outcomes?
SPEAKER_01Sure, other countries do have similar regulatory structures. Of course, we we we think that ours is the best and the most strident, but other countries absolutely have regulatory structures. You know, Japan has a very rigid regulatory um environment, Europe does as well, Canada does as well. And so in general, you know, when we seek patents, we'll seek patents in different regions of the world as well, but they're also regulatory agencies governing that, you know, across the world. The FDA is the one for the for the United States Food and Drug Administration.
DavidChanging subjects a little bit, one of the things that, as I teased in the opener that we talked about offline, is a problem that relates around diversity. Now, we've had some conversations on the podcast about diversity and hiring and the richness and the pros and the and things that that brings to an agency in terms of their overall culture and their makeup and their thought process and their decision-making process. But you and I were speaking about diversity in almost a pejorative way or a way that certainly has a negative, and that is around the area of clinical trials. I was not aware of that. And I'd like you to make our audience aware of what that issue is and what kinds of problems it might be creating.
SPEAKER_01Sure. You know, access to clinical trials traditionally in in certainly in the United States has has not been something that has been readily available to minority communities. And there are a number of reasons for that. The number one reason is is probably trust and trust in the system or lack thereof. But clinical trials are ongoing um at every major university, certainly at big uh hospital systems uh like Piedmont, there will be a very healthy research program. And clinical trials afford the opportunity for two things. One, they f afford an opportunity to access tomorrow's uh treatment today, and so ahead of FDA regulation, so you have an opportunity for treatment that's coming down the pike and that is not yet available to the general public. If minority populations are not participating in these trials, certainly the drug trials, but also the device trials, then as we develop new inventions and new innovations and new paradigms that continue to move the health of our population forward, anyone within the minority population has a risk of being left behind because those drugs and devices that are being developed were developed without their enrollment, without their representation, and therefore it's unclear if the drugs or devices actually have any relevance to these populations at all. And so we talk about efficacy of drugs and devices, meaning how well they work. If the majority of enrollees in a trial are all males of European descent, when we are ready to prescribe that drug, that drug goes out to the entire population. It goes out to women, it goes out to African Americans, it goes out to Japanese, it goes out to Hispanics, but it was really only tested on European males, and they're the only ones that we really know are benefiting. They're also the only ones where we really have great data on what the side effects are. And so traditionally what has happened is we extrapolate that data and apply it to other populations, but it's not at all clear that that's what's happening. And there's been this just disparate gap between minorities participating in trials and having access to really good clinical care that comes with participation in clinical trials and not having that access. I think oftentimes physicians as well that represent those communities and take care of those communities are not connected to academic institutions, not connected to large medical centers in a way that provides a relationship such that they can be involved and lead clinical trials and also refer their patients. So there are a number of complicating factors, but as we move forward into personalized medicine, customized medicine, um genomics, uh by whatever term that you know it, if we do not participate in trials and have a plethora of participation that represents a swath across all of America and indeed across all of the world, it becomes increasingly clear that the medications that are developed will not have uh relevance to our populations. Therefore, it it increases the health gap and the health disparity gap, clinical trials.
DavidWell, the the FDA doesn't have any requirements about diversity within a study population?
SPEAKER_01So currently the FDA does not. What the FDA requires is a specific amount of uh percentage of Americans have to be represented in trials because sometimes these trials are large global trials and we want to have a specific representation of Americans. But there hasn't been anything specific on what that makeup of Americans will be. Now, unofficially, the FDA is continuing to move in that direction, and more forward-thinking institutions are also beginning to move in that direction such that we can ensure that the health disparities and health gaps in these countries don't continue to widen, fueled and fed by lack of access to clinical trials, developing drugs that not only may not help different African American or minority populations, but could also harm them. We don't know what the interactions would be because we're not representing those populations in the clinical trials. And so it's a very slippery slope.
DavidSo how do you solve the problem in the near term if the FDA moves kind of deliberately, let's say, is for lack of a nicer word? Is it a question of awareness and reaching out to the minority communities and the physicians in those communities?
SPEAKER_01It certainly is awareness. I think it starts uh with the physicians. If physicians are involved or physicians um are advocating to the patient, the number one reason that a patient will enroll in a trial is that their trusted physician recommends it to them or suggests it to them. So you have to be in a relationship with a physician that's a trusted relationship. Majority of minority populations seek their care from people who look like them, such that there's cultural relevance, there's an understanding, there is not embarrassment or withholding of information, and there's that feeling that the person completely understands their perspective and their whole being. However, those physicians often are also disconnected from clinical trials, which generally are at large academic institutions and are also generally led by males of European descent. And so we have to begin to bridge that gap. Minority communities have a lack of trust because of all types of terrible things that have been done to communities, certainly the African American community, in the name of clinical trials and the name of research. And that is, you know, not to be taken lightly. Those are experiences that people don't want to willingly move forward and have again.
DavidSure. Completely understandable. So we've got about a minute left. In terms of innovations, where do you see the future? Where do you see this all going?
SPEAKER_01So that is the million-dollar question. It is going in um multiple directions all simultaneously. And I think as we look out on the horizon, we will see an uh increase in consumerism, an increase in empowerment of the patient over their health care and healthcare decisions and uh management of healthcare documents. We will see unanticipated competitors coming into the health space and in many ways controlling the patient population. And we will see probably unforeseen marriages occur between health systems and other companies as we move towards more creative, inventive, cost-effective ways of uh managing patients as we move into the future.
DavidWell, it certainly sounds like it's going to be chaotic and yet a lot of fun and a lot of opportunity for change, and all of those are good things. So we hope that you'll come back and join us again and maybe give us an update. Dr. Jane Morgan, Director of Innovation at Piedmont Healthcare. Thank you so much for sharing your expertise with our audience.
SPEAKER_01Thank you.
AnnouncerI appreciate being here. The Shift Shapers Podcast is a production of Shift Shaper strategies and may not be reproduced or quoted in whole or in part without our express written permission. Copyright 2020, all rights reserved.